Immunai IPO: Investment Opportunities & Pre-IPO Valuations

Company details

Immuani develops solutions for oncology treatments and auto-immune disorders by utilizing AI and ML technology to assist in mapping and to provide insights into the reprogramming of the immune system.

immunai.com

Sector

Healthcare

Subsector

Biotech & Pharma

Founded

2018

Headquarters

New York, NY, United States

Forge Price ¹

Price not yet available

Post-Money Valuation ³

$1.15B

Total Funding

$295.22MM

LFR Price per Share

$xx.xx

Last Funding Share Class

Series C-1

Learn more about Immunai

To invest in Immunai pre-IPO

Can you invest in Immunai pre-IPO?

Immunai is a privately held company and is not publicly traded, therefore investing in Immunai pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can learn more about Forge’s Secondary Marketplace and how to invest in private companies before their potential IPO. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.

Can you sell shares of Immunai before it goes public?

You can seek to sell your shares in Immunai while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

What is the pre-IPO value of my Immunai shares?

To determine the value of your Immunai shares, create a free account to gain access to Forge’s platform. In addition to the Forge Price, Forge Markets contains pricing information for hundreds of pre-IPO companies such as Last Closed Trade Price. A Private Market Specialist will also be available to assist you with any inquiries related to your Immunai shares. You can also learn more about how to sell your private shares before getting started.

Is Immunai a publicly traded company?

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

To learn more about Immunai potential IPO

Will Immunai go IPO?

Immunai has not yet filed for an IPO. However, it’s important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2025.

What is Immunai’s IPO price?

The Immunai IPO price does not exist at this time, as Immunai is still a private company and has not yet conducted an IPO. To explore secondary market data and access private market pricing details and data that may be related to Immunai register for Forge Markets, today.

When was Immunai founded?

Immunai was founded in 2018.

What is Immunai funding to date?

Immunai has raised $295.22MM to date.

Immunai major investors

8vc

Icon Ventures

Koch Disruptive Technologies

Immunai funding rounds and valuation

Funding history chart

Funding round details

	Funding Date	Share Class	Amount Raised	Price per Share	Post-Money Valuation	Key Investors
	10/27/2021	Series C-1	$204.34MM	$xx.xx	$1.15B	8vc, Alexanria Venture Investments, Icon, Koch Disruptive Technologies, Piedmont, Talos Vc
Price per Share $xx.xx Shares Outstanding 1,094,753 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 0.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors 8vc, Alexanria Venture Investments, Icon, Koch Disruptive Technologies, Piedmont, Talos Vc
	10/27/2021	Series C-2	$15MM	$xx.xx	$1.15B	8vc, Alexanria Venture Investments, Icon, Koch Disruptive Technologies, Piedmont, Talos Vc
Price per Share $xx.xx Shares Outstanding 172,800 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 0.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors 8vc, Alexanria Venture Investments, Icon, Koch Disruptive Technologies, Piedmont, Talos Vc
	02/11/2021	Series B-1	$55.66MM	$xx.xx	$240.97MM	Catalio Capital Management, Dexcel Pharma, Duquesne Family, Schusterman Foundation, Tlv Partners, Viola Ventures
Price per Share $xx.xx Shares Outstanding 1,088,327 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 0.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Catalio Capital Management, Dexcel Pharma, Duquesne Family, Schusterman Foundation, Tlv Partners, Viola Ventures
	02/11/2021	Series B-2	$2.99MM	$xx.xx	$240.97MM	Catalio Capital Management, Dexcel Pharma, Duquesne Family, Schusterman Foundation, Tlv Partners, Viola Ventures
Price per Share $xx.xx Shares Outstanding 73,326 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 0.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Catalio Capital Management, Dexcel Pharma, Duquesne Family, Schusterman Foundation, Tlv Partners, Viola Ventures
	05/14/2020	Series A	$12.05MM	$xx.xx	$38.16MM	Tlv Partners, Viola Ventures
Price per Share $xx.xx Shares Outstanding 956,259 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 0.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Tlv Partners, Viola Ventures
	05/14/2020	Series Seed-2	$5.3MM	$xx.xx	$38.16MM	Tlv Partners, Viola Ventures
Price per Share $xx.xx Shares Outstanding 672,817 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 0.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Tlv Partners, Viola Ventures
	05/14/2020	Series Seed-1	$214,992.12	$xx.xx	$38.16MM	Tlv Partners, Viola Ventures
Price per Share $xx.xx Shares Outstanding 36,390 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 0.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Tlv Partners, Viola Ventures

Access Stock Price

Private companies exploring an IPO

					Last Funding Round
Company		Forge Price	Forge Price Change ⁵	Last Closed Trade	Share Class	Post-Money Valuation	Price per Share	Amount Raised
	OpenAI	$469.47	-0.01%	$xx.xx	Funding Round	--	--	--
	Anduril	$40.88	-3.86%	$xx.xx	Series G	$30.5B	$xx.xx	$2.5B
	Cerebras	$31.39	-0.35%	$xx.xx	Series F-1	$2.87B	$xx.xx	$420MM
	Figma	$38.00	+0.03%	$xx.xx	Series E	$10B	$xx.xx	$200MM
	Kraken	$27.88	+8.02%	$xx.xx	Series B	$5.52B	$xx.xx	$52.5MM
	Netskope	$14.50	+8.45%	$xx.xx	Series H	$7.5B	$xx.xx	$300MM
	Klarna	$37.31	+21.02%	$xx.xx	Unknown	--	--	--
	Discord	$239.72	+6.61%	$xx.xx	Series I	$15B	$xx.xx	$500MM
	Cohesity	$17.00	+8.49%	$xx.xx	Series H-1	$4.69B	$xx.xx	$27.5MM
	Shein	--	--	$xx.xx	--	--	--	--

See Tech IPO Calendar

Forge, your trusted partner for pre-IPO insights and Immunai data

Forge is the trusted platform for buying and selling pre-IPO shares. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

First time buying private market stock?

New to selling your private company stock?

Updated on: Jan 22, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.
Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.

Immunai IPO